scholarly journals Ceftolozane-tazobactam pharmacokinetics during extracorporeal membrane oxygenation in a lung transplant recipient

2018 ◽  
Author(s):  
Fabio Arena ◽  
Luca Marchetti ◽  
Lucia Henrici De Angelis ◽  
Enivarco Maglioni ◽  
Martina Contorni ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Transplant Recipient ◽  
Extracorporeal Membrane Oxygenation ◽  
Lung Transplant ◽  
Drug Exposure ◽  
Pulmonary Infection ◽  
Lung Transplant Recipient ◽  
Membrane Oxygenation ◽  
Optimal Drug

AbstractCeftolozane-tazobactam pharmacokinetics during extracorporeal membrane oxygenation (ECMO) has not been previously studied. In this work we report on the ceftolozane and tazobactam plasmatic levels in a lung transplant recipient during ECMO, treated with ceftolozane-tazobactam (2g/1g, intravenously every 8 h, 1 h infusion) for a Pseudomonas aeruginosa pulmonary infection. Ceftolozane Cmax and Cmin, monitored during 96 hrs, remained above 60 and 20 μg/mL, respectively, with optimal drug exposure (100% %TMIC). Tazobactam levels were above 1.9 μg/mL.

scholarly journals Ceftolozane-Tazobactam Pharmacokinetics during Extracorporeal Membrane Oxygenation in a Lung Transplant Recipient

2019 ◽  
Vol 63 (3) ◽  
Author(s):  
Fabio Arena ◽  
Luca Marchetti ◽  
Lucia Henrici De Angelis ◽  
Enivarco Maglioni ◽  
Martina Contorni ◽  
...  
Keyword(s):  
Transplant Recipient ◽  
Extracorporeal Membrane Oxygenation ◽  
Lung Transplant ◽  
Lung Transplant Recipient ◽  
Membrane Oxygenation

scholarly journals InvasiveMicroascus trigonosporusSpecies Complex Pulmonary Infection in a Lung Transplant Recipient

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
Kelly E. Schoeppler ◽  
Martin R. Zamora ◽  
Noelle M. Northcutt ◽  
Gerard R. Barber ◽  
Gayle O’Malley-Schroeder ◽  
...  
Keyword(s):  
Transplant Recipient ◽  
Lung Transplant ◽  
Drug Exposure ◽  
Fungal Infections ◽  
Organ Transplant ◽  
Antifungal Prophylaxis ◽  
Lung Transplant Recipient ◽  
Invasive Infection ◽  
Solid Organ ◽  
High Incidence

Because of the high incidence of morbidity and mortality associated with invasive fungal infections, antifungal prophylaxis is often used in solid organ transplant recipients. However, this prophylaxis is not universally effective and may contribute to the selection of emerging, resistant pathogens. Here we present a rare case of invasive infection caused byMicroascus trigonosporusspecies complex in a human, which developed during voriconazole prophylaxis in a lung transplant recipient. Nebulized liposomal amphotericin B was used in addition to systemic therapy in order to optimize antifungal drug exposure; this regimen appeared to reduce the patient’s fungal burden. Despite this apparent improvement, the patient’s pulmonary status progressively declined in the setting of multiple comorbidities, ultimately leading to respiratory failure and death.

scholarly journals BDUMP: A Rare Case of Vision Loss in a Lung Transplant Recipient

2021 ◽  
Vol 40 (4) ◽  
pp. S509-S510
Author(s):  
M. Barraza ◽  
J. Rosenheck ◽  
B.C. Keller ◽  
I. Livshitz ◽  
M.M. Howsare
Keyword(s):  
Transplant Recipient ◽  
Rare Case ◽  
Lung Transplant ◽  
Vision Loss ◽  
Lung Transplant Recipient

Splenic abscess caused by Toxocara spp. in a lung transplant recipient, Marseille, France

2021 ◽  
Author(s):  
Quentin Balacheff ◽  
Jean‐Baptiste Lovato ◽  
Benjamin Coiffard ◽  
Coralie L’Ollivier ◽  
Nadim Cassir ◽  
...  
Keyword(s):  
Transplant Recipient ◽  
Lung Transplant ◽  
Splenic Abscess ◽  
Lung Transplant Recipient

scholarly journals Hemophagocytic Lymphohistiocytosis in a Lung Transplant Recipient

2021 ◽  
Vol 40 (4) ◽  
pp. S510
Author(s):  
D. Rudym ◽  
M. Lesko ◽  
S. Chang ◽  
Z. Kon ◽  
K. Sureau ◽  
...  
Keyword(s):  
Transplant Recipient ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Lung Transplant ◽  
Lung Transplant Recipient
Sign in / Sign up

Export Citation Format

Share Document